Genflow Biosciences

GENF · Main Market · Health Care · mcap £11m · 1.8p

Beta Briefing, track record and signals & risks are not ready for Genflow Biosciences yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 61 companies are already wired into a briefing: browse them.

Key announcements Monitoring checked today, 05:05

All · 36 Key · 29

Date	Type	Announcement	Day
09 Oct 26		Corporate Update Japanese patent granted for SIRT6 variants; additional animal health companies sign confidentiality agreements.	−2.2%
05 Oct 26	Results	Presentation of Interim Results SLAB canine study interim results show SIRT6c gene therapy reduced epigenetic age and was well tolerated.	−13.3%
29 Sep 26		Exercise of Warrants and Issue of Equity Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant	+0.0%
29 Sep 26	Results	Half-year Results Completed lead canine trial validating SIRT6 platform; raised £1.1m in H1 2026; expanded into glaucoma program.	+0.0%
08 Sep 26		Primary Endpoint in SLAB Clinical Trial Met SLAB clinical trial met primary endpoint in SIRT6 gene therapy trial in aged dogs with biological age reduction.	−2.4%
07 Sep 26		Appointment of Investor Relations Adviser Genflow appoints ON365 Partners as investor relations adviser, replacing Harbor Access.	+13.1%
03 Aug 26		Patent Update SIRT6 patent application for NAFLD published; Track One prioritized examination granted for foundational US patent.	+16.4%
13 Jul 26		Mid-Year Operational and Corporate Summary SLAB dog trial shows sustained safety and efficacy at three-month follow-up; non-dilutive Acuitas LNP collaboration secured.	−1.3%
22 Jun 26		Participation at BIO International Convention 2026 Independent Non-Executive Chairman attending BIO International Convention 2026 panel on RNA therapeutics.	+3.7%
17 Jun 26		Company to present at Animal Longevity Summit 2026 Genflow invited to present SLAB trial data at Animal Longevity Summit in October 2026.	−1.2%
08 May 26		Exercise of Warrants and Issue of Equity Genflow (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it has received notices of exercise of warrant	−7.7%
30 Apr 26	Results	Final Results FY25 results show progress in dog aging trial, MASH repositioning, and shift to mRNA delivery technology.	−1.1%
28 Apr 26		Expansion of Confidentiality Agreements Expanded confidentiality agreements with Tier-1 animal health companies for canine SIRT6 gene therapy programme review.	+12.0%
20 Apr 26		Strategic Technology Collaboration Genflow enters fully funded collaboration with Acuitas to integrate LNP delivery technology with its SIRT6 mRNA platform.	+16.9%
13 Apr 26		International Patent Publication Patent Cooperation Treaty application published for SIRT6 variants for muscular disease treatment.	+10.3%
08 Apr 26		Update on the Dog Study SLAB trial shows sustained safety and efficacy three months post-dosing in aged dogs receiving SIRT6 gene therapy.	−9.1%
02 Mar 26		Result of General Meeting Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meet	−5.0%
02 Mar 26		Receipt of First Tranche of Grant Received first tranche of €336,467 from €4 million Wallonia Region grant for GF-1002 development.	−5.0%
12 Feb 26	Results	Preliminary Interim Results From Dog Study SLAB trial of SIRT6 gene therapy in aged dogs shows survival benefit and safety with improvements in muscle mass and frailty.	+0.0%
11 Feb 26		Notice of GM Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is c	−9.5%
28 Jan 26		Administrative Approval of Grant & 2026 Priorities €4 million non-dilutive funding from Wallonia Region administratively approved for GF-1002 development.	−2.6%
19 Jan 26	Board change	Directorate Change Gad Berdugo appointed Independent Non-Executive Chairman; Tamara Joseph continues as Director.	+5.4%
08 Jan 26		Review of 2025 Genflow completed dog aging trial dosing with no adverse events; expects efficacy readout Q1 2026 and plans pipeline rationalization.	+0.0%
16 Dec 25		Completion of Dosing Phase of Canine Gene Therapy Completed dosing phase of canine SIRT6 gene therapy trial with no adverse events reported.	+1.4%
11 Dec 25		Genflow to Attend Healthcare Conference Genflow to attend the J.P. Morgan Healthcare Conference in January 2026.	−11.5%
22 Oct 25		Second European Patent Application Second European patent application for SIRT6 variant for NASH published in European Patent Bulletin.	−0.9%
20 Oct 25		Recognition of Patentability of Claims European Patent Office published SIRT6 variant patent application, entering final pre-grant phase.	−4.4%
10 Oct 25		Update on Animal Health Program SIRT6 gene therapy administered second time in dog aging study with no adverse effects reported.	+1.9%
09 Oct 25	Director dealing	Update, Equity Issue and PDMR Notification Terminated prior fundraise; raised £440k via share issue to CEO and existing shareholders at 1.1p per share plus warrants.	+90.9%

Company filings. Not investment advice.